10 743449

copi

PH7483 NP

### **CERTIFICATE OF MAILING**

Hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United these Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the commissioner for Patents, P.O. Box 1450, Alexandria, VA 23/313-1450

Signature

Sammy G. Duncan, Jr.

Type or print name

11/2/11 Date

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Certificate of Corrections Branch Commissioner for Patents PO BOX 1450 Alexandria, VA 22313-1450

IN RE APPLICATION OF TAEKYU LEE, ET AL PATENT NO: 7109339 FILED: 12/19/2003

FOR: SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS

Certificate

NOV 0 8 2006

of Correction

# <u>FOR PTO MISTAKE (37 C.F.R.§1.322(a))</u>

Sir:

Attached, in duplicate, is Form PTO-1050, with at least one copy being suitable for printing.

In that this error was incurred by the Office, no fee is believed to be due. If any fee not accounted for is due in connection herewith, please charge such fee to Deposit Account No. 19-3880 of the undersigned.

Please send the Certificate to the address associated with customer account number 23914.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

Sammy G. Dungan, Jr., Ph.D.

Attorney for Applicant Reg. No. 46,675

Phone: 609-252-6270

Date: 11/2/06

NOV - 9 2006

### UNITED STATES PATENT AND TRADEMARK OFFICE

# CERTIFICATE OF CORRECTION

PATENT NO

7,109,339

Page 1 of 2

DATED:

September 19, 2006

INVENTOR(S)

Taekyu Lee et al.

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims: Column 160, Line 35 insert the following:

C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>41</sup>, and

5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R<sup>41</sup>;

 $R^{2a}$  is H, C<sub>1-4</sub> alkyl, (aryl)C<sub>1-4</sub> alkyl-, or (C<sub>3-6</sub> cycloalkyl)C<sub>1-4</sub> alkyl-;

R<sup>4a</sup> is H or C<sub>1-4</sub> alkyl;

 $R^5$  is H,  $C_{1-4}$  alkyl substituted with 0-2  $R^{20}$ ,

-C(=O)(C<sub>1-4</sub> alkyl), -C(=O)O(C<sub>1-4</sub> alkyl), or C<sub>1-4</sub> haloalkyl;

 $R^6$  is selected from

-OCF<sub>3</sub>, -SCH<sub>3</sub>, -CF<sub>2</sub>CF<sub>3</sub>, -O-R<sup>11</sup>,

-OCF<sub>2</sub>CF<sub>3</sub>, -OCF<sub>2</sub>H, -OCF<sub>2</sub>CH<sub>3</sub>,

 $-S(=O)-R^{11}$ ,  $-S(=O)_2-R^{11}$ ,  $-S(=O)-NR^{10}-R^{11}$ ,

 $-S(=O)_2-NR^{10}-R^{11}$ ,  $-CH_2O-R^{11}$ ,  $-CH_2S-R^{11}$ ,

 $CH_2S(=O)-R^{11}$ ,  $CH_2S(=O)$  2-R<sup>11</sup>,- $CH_2NR^{10}-R^{11}$ , - $C(=O)NR^{10}-R^{11}$ 

 $C_{1-4}$  haloalkyl, ( $C_{1-4}$  haloalkyl)oxy;

C<sub>2-4</sub> alkenyl substituted with 0-2 R<sup>20</sup>,

C<sub>2-4</sub> alkynyl substituted with 0-1 R<sup>20</sup>, and

 $C_{3-6}$  carbocyclic residue substituted with 0-3  $R^{21}$ ,

R<sup>7</sup> and R<sup>9</sup> are independently selected from

-OCF3, -CF2CF3, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, and

(C<sub>1-4</sub> haloalkyl)oxy;

NOV - 9 2006

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 7,109,339

Page 2 of 2

DATED:

September 19, 2006

INVENTOR(S) :

Taekyu Lee et al.

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims: Claim 3, Column 166, Line 26 replace:

R<sup>4</sup>a with R<sup>4a</sup>

MAILING ADDRESS OF SENDER:

PATENT NO. 7,109,339

Sammy G. Duncan, Jr., Ph.D. Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-6270

FORM **PTO-1050** 

### UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO

7,109,339

Page 1 of 2

DATED:

September 19, 2006

Taekyu Lee et al. INVENTOR(S)

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims: Column 160, Line 35 insert the following:

C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>41</sup>, and

5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N. O. and S substituted with 0-3 R<sup>41</sup>;

 $R^{2a}$  is H,  $C_{1-4}$  alkyl,  $(aryl)C_{1-4}$  alkyl-, or (C<sub>3-6</sub> cycloalkyl)C<sub>1-4</sub> alkyl-;

R<sup>4a</sup> is H or C<sub>1-4</sub> alkyl;

R<sup>5</sup> is H, C<sub>1-4</sub> alkyl substituted with 0-2 R<sup>20</sup>,  $-C(=O)(C_{1-4} \text{ alkyl})$ ,  $-C(=O)O(C_{1-4} \text{ alkyl})$ , or  $C_{1-4}$  haloalkyl;

R<sup>6</sup> is selected from

-OCF3, -SCH3, -CF2CF3, -O-R<sup>11</sup>,

-OCF2CF3, -OCF2H, -OCF2CH3,

 $-S(=O)-R^{11}$ ,  $-S(=O)_2-R^{11}$ ,  $-S(=O)-NR^{10}-R^{11}$ ,

 $-S(=O)_2-NR^{10}-R^{11}$ ,  $-CH_2O-R^{11}$ ,  $-CH_2S-R^{11}$ ,

 $CH_2S(=O)-R^{11}$ ,  $CH_2S(=O)$  2-R<sup>11</sup>,- $CH_2NR^{10}-R^{11}$ ,- $C(=O)NR^{10}-R^{11}$ 

C<sub>1-4</sub> haloalkyl, (C<sub>1-4</sub> haloalkyl)oxy;

C2-4 alkenyl substituted with 0-2 R<sup>20</sup>,

C<sub>2-4</sub> alkynyl substituted with 0-1 R<sup>20</sup>, and

C<sub>3-6</sub> carbocyclic residue substituted with 0-3 R<sup>21</sup>.

R<sup>7</sup> and R<sup>9</sup> are independently selected from

-OCF3, -CF2CF3, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, and

(C<sub>1-4</sub> haloalkyl)oxy;

NOV - 9 2006

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 7,109,339

Page 2 of 2

DATED:

September 19, 2006

INVENTOR(S) :

Taekyu Lee et al.

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims: Claim 3, Column 166, Line 26 replace:

R<sup>4</sup>a with R<sup>4a</sup>

MAILING ADDRESS OF SENDER: Sammy G. Duncan, Jr., Ph.D. Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

(609) 252-6270

**FORM PTO-1050** 

PATENT NO. 7,109,339